Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

NanoViricides Anticipates FluCide™ Drug Candidates to be Effective Against H7N9

Published: Tuesday, April 23, 2013
Last Updated: Tuesday, April 23, 2013
Bookmark and Share
NanoViricides, Inc. anticipates that the oral and injectable FluCide™ drug candidates would be effective against the novel H7N9 strain that has caused human fatalities in China in recent months.

Both the injectable FluCide drug for use in severely ill patients with influenza, and the oral FluCide drug for less sick out-patients bear a virus-binding ligand that mimics sialic acid. Moreover, this ligand is capable of substituting for both the mammalian form (sialyl-alpha2,6-gal-) or the avian form (sialyl-alpha2,3-gal-). Since the novel H7N9 (2013) virus is transitioning from avian to human host, the dual biomimetic capability of our FluCide ligand should have a favorable impact.

CDC, and scientists from China and Japan have reported, based on the genetic structure of the novel H7N9 virus, that this virus is likely to bind well with the mammalian form of sialic acid. This virus is also reported to bear other mutations that enable it to infect mammalian hosts effectively. Existing H7-vaccine viruses are not well matched to this novel H7N9 virus, and new vaccine development will take some time. This H7N9 is resistant to amantadine and rimantadine, as are most US and European Influenza A virus strains. It is suggested to be susceptible to neuraminidase inhibitors such as oseltamivir (Tamiflu®) and zanamivir (Relenza®), but certain mutations suggest resistance to these drugs. CDC authors Dr. Uyeki and Dr. Cox note that clinical research is urgently needed on new antiviral agents, including drugs with different mechanisms of action.

FluCide is based on a completely novel mechanism of action wherein the drug micelle is designed to bind to the virus particle via multi-dentate interactions, and then to spread onto the virus surface via lipid-lipid interactions with the viral lipid coat, thereby covering the entire virus particle. Some viruses can also be dismantled by such attack. This is similar to antibodies, in that antibodies bind to the virus particle and cover its cell-binding sites. However, each antibody (IgG) binds via only two points to the virus, whereas a single polymer chain in FluCide can be designed to have as many as twenty or even larger numbers of virus-binding ligands, that are uniformly spaced along the chain. In addition, an antibody itself alone is generally insufficient for viral destruction. The antibody-coated virus particle or a resulting immuno-precipitate must be further acted upon by the human immune system in various ways for the virus infection to be controlled. In contrast, a nanoviricide® agent is designed to perform its antiviral effect even if the immune system is compromised. Further, antibodies are highly specific to a virus strain, and since influenza virus can mutate rapidly it can escape the antibody. In contrast, the virus-binding ligands on FluCide are chosen to mimic the sialic acid. Binding to sialic acid is an absolutely required first step for any influenza virus to infect a human host. Thus, a proper choice of virus-binding ligand allows us to suggest that FluCide should be effective against the novel H7N9 strain of influenza.

Both the oral and the injectable FluCide drug candidates have shown extremely high effectiveness in highly lethal mouse models of two distinctly different influenza A virus infections, viz. H1N1 and H3N2, indicating that FluCide drugs indeed have a broad-spectrum effect against influenza viruses, irrespective of the subtype or strain.

In these highly lethal studies, FluCide drug candidates have achieved complete survival (22+ days), while in contrast, Tamiflu® (oseltamivir) resulted in only 8-9 days survival, and the untreated animals die within 5 days. The FluCide oral and injectable drug candidates also protected the lungs of the animals much better than did oseltamivir, indicating a clear benefit. The protection from influenza virus was clearly reflected in the strong increase in survival time in the FluCide-treated animals as compared to oseltamivir. The FluCide drugs were seen to be far superior to Tamiflu also in terms of viral load reduction. The FluCide drugs were extremely well tolerated, in contrast to oseltamivir. No dose-limiting side effects have been seen for our FluCide candidates as yet, indicating that in a severely ill patient, the dosage of FluCide can be increased even further. In these animal studies, the mouse serves only as a “test tube” and FluCide is designed to attack the virus (not the host). Thus the results are expected to correlate well with the impending human clinical studies.

Binding to sialic acid on the cell surface is a completely conserved property of all influenza viruses. The avian influenza viruses tend to prefer binding to the a-2,3- variant of sialic acid, whereas those causing disease in humans tend to prefer binding to the a-2,6- variant. Pigs and some other species serve as “mixing species” where both the avian and mammalian viruses can grow, and further, avian viruses can mutate to mammalian viruses.

The Company has previously reported that it is enabling cGMP production of the FluCide drug candidates in the near future. The Company reports further that the design phase of the cGMP clinical batch production and laboratory facilities is completed and bidding phase for subcontracts has begun.

The Company has held a pre-IND meeting with the US FDA at the end of March, 2012, for the injectable FluCide drug candidate, and has been working on the IND enabling studies for this drug. The Company has previously reported that it has successfully developed the very first orally bio-effective nanomedicine. This development has added the oral FluCide as an additional drug candidate to the Company’s pipeline. Oral anti-influenza drugs have estimated market size of $4B to $7B at present, which could expand substantially if a highly effective anti-influenza drug such as FluCide is developed.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Antioxidants Cause Malignant Melanoma to Metastasize Faster
Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice.
Have Your Drug Nano-Delivered Via Microbubble
A UC engineering professor is working to develop effective nanoparticle-bubble drug delivery systems to access precise locations in the body to treat medical conditions such as cancer, eye disease and spinal disc degeneration.
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Tension Helps Heart Cells Develop Normally in the Lab
Stanford engineers have uncovered the important role tension plays in growing heart cells out of the body.
Controlling Body Temperature in Response to 'Fight or Flight'
New research in The FASEB Journal suggests that blocking TRPV1 protein causes an increased release of noradrenaline, leading to an increase in core body temperatures.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos